Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Ori Biotech
Ori Biotech
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Ori Biotech expands board of directors and scientific advisory board
Dr Annalisa Jenkins will join Ori’s board of directors, and Robert Preti will join its scientific advisory board
Finance
Ori Biotech appoints senior management roles
Stuart Milne and Kevin Gordon will join the company as CTO and Chief Data & Operating Officer respectively
Finance
Ori Biotech selected to join CGT consortium
The consortium has identified the development of process analytical technology as critical to the success of the industry
Manufacturing
Ori Biotech and Vineti collaborate on digital platform for CGTs
This partnership follows on from Ori’s $30 m Series A funding round in 2020, and Vineti’s release of its PTM Essentials solution for advanced therapy clinical trials
Finance
ATMPS and Ori Biotech collaborate on an integrated digital platform
The non-exclusive partnership will result in the integration of Ori’s proprietary CGT manufacturing platform’s data architecture with ATMPS’ Hataali secure data sharing platform
Finance
Ori Biotech completes $30m series A funding round
The Series A investor syndicate was led by the life sciences investment team at Northpond Ventures alongside Octopus Ventures
Pharmaceutical
Ori Biotech partners to test novel cell therapy manufacturing platform
Achilles Therapeutics has agreed to test Ori’s manufacturing platform in its proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process
Subscribe now